PROPOFOL INJECTION 10 MG
PROPOFOL : 10 MG · DIN 02437643 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is PROPOFOL INJECTION?
PROPOFOL INJECTION 10 MG contains PROPOFOL : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02437643, held by FRESENIUS KABI CANADA LTD, supplied as EMULSION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 01-Jun-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PROPOFOL INJECTION used for?
Induction and maintenance of general anesthesia; conscious sedation for surgical/diagnostic procedures; sedation during intensive care for intubated, mechanically ventilated adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02437643 |
|---|---|
| Brand name | PROPOFOL INJECTION |
| Generic / active ingredient | PROPOFOL : 10 MG |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 10 MG |
| Dosage form | EMULSION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | N01AX10 PROPOFOL |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Jun-2015 |
How is it administered?
Individually titrate to effect. Induction: 2-2.5 mg/kg (adults <55). Maintenance: 0.1-0.2 mg/kg/min. ICU sedation: 0.005-0.05 mg/kg/min (max 4 mg/kg/h). Use aseptic technique.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Do not freeze. (Standard storage typically 15-30°C, though specific range not explicitly in snippet, 'Do not freeze' is specified).
How is it supplied?
Single-use parenteral product (specific container sizes not listed in provided text, but noted as single-use).
Contraindications
Hypersensitivity to propofol, lipid emulsions, eggs/egg products, or soybeans/soy products. Contraindicated for sedation of children 18 years or younger receiving intensive care.
Warnings and precautions
Risk of fatal respiratory complications without airway care. Risk of hypotension, apnea, and sepsis if aseptic technique fails. Monitor for Propofol Infusion Syndrome (PIS) and lipemia.
What can be used instead?
Other Canadian products sharing ATC code N01AX10 PROPOFOL. 4 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DIPRIVAN 1% | 10 MG | EMULSION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 02018950 |
| PROPOFOL INJECTION | 10 MG | EMULSION | BAXTER CORPORATION | MARKETED | DIN 02244379 |
| PROPOFOL INJECTION | 10 MG | EMULSION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02525879 |
| PROPOFOL | 10 MG | EMULSION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 02468336 |
| PROPOFOL INJECTION | 10 MG | EMULSION | STERIMAX INC | APPROVED | DIN 02559692 |
| PROPOFOL INJECTION | 10 MG | EMULSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02236887 |
| PROPOFOL INJECTION | 10 MG | EMULSION | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 02241504 |
| PROPOFOL INJECTION | 10 MG | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02242973 |
| PROPOFOL-II INJECTION | 10 MG | EMULSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02376865 |
| TEVA-PROPOFOL | 10 MG | EMULSION | TEVA CANADA LIMITED | DORMANT | DIN 02437961 |
Who else supplies PROPOFOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PROPOFOL appears in 1483 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.